Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma

Area of Science:

• Oncology
• Dermatology
• Genetics

Background:

• Approximately 50% of melanomas harbor a BRAF mutation.
• BRAF V600K represents 10% of these mutations, making it the second most common driver after V600E.
• No specific clinical or therapeutic guidelines exist for the BRAF V600K melanoma subgroup.

Purpose of the Study:

• To identify common clinical and biological traits of melanoma patients with BRAF V600K mutation.
• To review adopted therapeutic strategies for this specific patient population.
• To address the unmet medical need and poor prognostic implications of BRAF V600K melanoma.

Main Methods:

• Analysis of scientific articles, including pivotal clinical trials.
• Identification of common clinical characteristics.
• Review of biological traits and therapeutic approaches.

Main Results:

• BRAF V600K melanoma is more prevalent in Caucasian, male, and elderly individuals with a history of sun damage.
• This subgroup exhibits poorer prognosis with no identified specific prognostic factors.
• Melanoma V600K shows reduced dependence on the ERK/MAPK pathway, increased PI3KB expression, and inhibited antiapoptotic pathways.

Conclusions:

• Both BRAF/MEK inhibitor targeted therapy and immunotherapy are effective for BRAF V600K melanoma.
• Insufficient evidence currently supports a definitive first-line treatment recommendation for advanced stages (IIIC unresectable/IV).
• BRAF V600K melanoma remains an unmet medical need and a marker of poor prognosis in cutaneous melanoma.